Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 186

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 186
---
, 2025, Mr. Huen, Aptorum’s Charirman and CEO, held a video conference call with Dr. Alidad Mireskandari, Chief Executive Officer of DiamiR and Dr. Kira Sheinerman, Executive Director of DiamiR for an introductory discussion. Other participants included representative of Hunter Taubman Fischer & Li. In connection with Aptorum’s review of the potential transaction with DiamiR, Aptorum and its advisors completed customary diligence, including, meetings with the management of DiamiR, customary legal review of DiamiR business and contracts, and customary financial diligence. On April 14, 2025, Aptorum sent DiamiR an initial draft non -bindingletter of intent (the “LOI”) and term sheet. Following further negotiations, including calls on April 22, 2025 and May 6, 2025 to discuss the contemplated business combination structure, and the respective approvals of each company’s board of directors, the LOI was signed on May 12, 2025, and further amended on June 2, 2025. The LOI contemplated the acquisition of DiamiR by 94 Aptorum, with DiamiR surviving as a wholly owned subsidiary of Aptorum, the entry into the Management Services Agreement and Intellectual Property Agreement (as further described in this proxy and prospectus) during the interim period between signing of the Merger Agreement and consummation of the Merger, the redomestication of Aptorum in Delaware, and other requirements that would be needed prior to the consummation of a merger. Aptorum, in connection with the proposed merger with DiamiR, determined it was in the best interest of the Company to raise additional proceeds by the public offering of the Company’s equity securities by means of a Form F -1filing with the SEC, which proceeds are intended for working capital, to support DiamiR’s biopharma services franchise, increase lab throughput, advance pipeline products, including CogniMIR ®, test for glioblastoma and other LDTs under CLIA guidelines, and other general corporate purposes. Between May 12, 2025 and July 13, 2025, Aptorum and DiamiR, and their respective legal counsels, prepared, reviewed, and negotiated the terms of the Merger Agreement, disclosure schedules, and other ancillary transaction agreements, and prepared the necessary disclosures as required on Forms S -4and F -1to